Genflow Biosciences PLC (LSE:GENF, OTCQB:GENFF) has announced new collaborations with Revatis SA and EXO Biologics on two new research programs, backed by non-dilutive financial backing from the Government of Wallonia in Belgium.
The two research programmes are part of a broader innovation partnership that the Walloon Government has launched with an €81 million budget, dedicated to advanced therapy medicinal products (ATMPs).
Bango PLC (AIM:BGO, OTCQX:BGOPF) posted a 62% increase in revenues to $46.1 million (£36.3 million) last year as a host of new contracts started to contribute.
This growth was attributed to Bango's payments segment during the second half of the year.
Rainbow Rare Earths Limited said it hosted a US Congressional staff delegation at its Phalaborwa project in South Africa following the International Development Finance Corporation (DFC) commitment of $50 million of new investment in the operation.
The funding, announced at the COP28 United Nations Climate Change Conference on December 3, underscores the global push for responsibly increasing the production of metals vital for clean energy technologies.
Arecor Therapeutics PLC (AIM:AREC) has received a European patent (EP3618840) for its fast-acting insulin products, AT278 and AT247, further protecting the intellectual property underpinning their unique formulations.
This development follows the company's recent patent acquisitions in Australia, India, and Mexico.